Two independent peer-reviewed clinical studies validate remote Biophysical Profile assessment, supporting Pulsenmore’s strategy to expand its platform through scalable SaaS applications.

 

Ramat Gan, Israel, July 15, 2026 – Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced growing clinical evidence supporting the expansion of its home ultrasound platform beyond individual ultrasound measurements toward more advanced prenatal assessments.

Two independent peer-reviewed clinical studies, published in the International Journal of Gynecology & Obstetrics (IJGO) and AJOG MFM and conducted by leading medical centers in the United States and Israel, demonstrated that the ultrasound components of the Biophysical Profile (BPP), one of the most widely used fetal surveillance examinations during pregnancy, can be successfully performed using Pulsenmore’s home ultrasound platform under real-time clinician guidance.

Pulsenmore’s technology enables pregnant women to perform physician-prescribed ultrasound examinations at home using a compact ultrasound device connected to their own smartphone. Each examination is securely transmitted to a physician for remote review and clinical decision-making. To date, Pulsenmore’s platform has supported more than 250,000 home ultrasound examinations.

BPP is an established, reimbursed clinical examination widely used around the world. Approximately 10% of pregnancies require repeated antenatal fetal surveillance, and BPP is one of the most commonly used assessment tools for evaluating fetal well-being in pregnancies complicated by diabetes, fetal growth restriction, decreased fetal movements, and post-term pregnancy. Its recurring utilization and existing reimbursement pathways make BPP an attractive target for software-enabled remote care.

Two studies, led by Dr. Alex Peahl and colleagues at the University of Michigan and Prof. Eran Hadar and Dr. Anat Pardo at Rabin Medical Center, Israel, enrolled a total of 55 pregnant women. Both studies consistently demonstrated high agreement between home ultrasound examinations and conventional hospital-based assessments of the ultrasound components of the BPP, with strong concordance across fetal movement, fetal breathing, fetal tone, fetal presentation, fetal heart rate, and amniotic fluid assessment. The findings support the feasibility of performing this complex fetal surveillance examination remotely under clinician guidance.

Prof. Eran Hadar and Dr. Anat Pardo, the Beilinson study’s principal investigators, commented:

“For the first time, we demonstrated that a complex ultrasound examination can be performed remotely using a home ultrasound device operated by the pregnant woman herself, while maintaining high agreement with hospital-based examinations. This approach has the potential to improve access to maternal-fetal care, reduce unnecessary hospital visits, and become an important component of future digital pregnancy care.”

Dr. Alex Peahl, the University of Michigan study’s principal investigator, commented:

“The BPP4Me study is an important first step in making antenatal testing available for all patients, even those facing the greatest barriers to care.”

Together, these independent studies strengthen the clinical evidence supporting the expansion of Pulsenmore’s platform from individual ultrasound measurements to more comprehensive prenatal assessments. They also support the Company’s strategy of expanding the capabilities of its existing platform through dedicated software-based clinical applications, creating opportunities to introduce Software-as-a-Service (SaaS) modules that can expand Pulsenmore’s addressable market while increasing the value of its existing installed base.

Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, said:

“Each validated clinical application strengthens the value of our platform for healthcare providers and expands our addressable market through a SaaS-driven strategy. We believe this approach unlocks new recurring revenue opportunities and positions us for sustained long-term growth.”

About Pulsenmore

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care.

For more information, visit www.pulsenmore.com.

Forward-Looking Statements
This press release contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “goal,” “due,” “predict,” “plan,” “project,” “continue,” “potential,” “positioned,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding the Company’s strategy to expand its platform through software-based clinical applications, the potential development and commercialization of future SaaS modules, potential future regulatory clearances, anticipated market opportunities, expected adoption by healthcare providers, the expansion of the Company’s addressable market, future recurring revenue opportunities, and the Company’s long-term growth strategy. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passage of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Annual Report on Form 20-F, filed with the SEC on March 30, 2026. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

   

Investor Contact:

Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com

The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company’s home ultrasound platform.

RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in connected home ultrasound technology, today announced that it has been selected to participate in Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority (IIA) and the Ministry of Health. Pulsenmore will receive funding from the IIA as part of a project.

The program is designed to accelerate the adoption of breakthrough healthcare AI technologies through a unique regulatory framework that enables companies to develop, evaluate and clinically validate innovative solutions in close collaboration with regulators and the healthcare system. Its objective is to establish a clear and efficient pathway for the integration of these technologies into healthcare systems in Israel and worldwide.

Pulsenmore’s home ultrasound platform enables pregnant women to perform physician-prescribed ultrasound scans from home using the company’s ultrasound device connected to their personal smartphone. Each examination is securely transmitted to a physician for interpretation and clinical decision-making. Today, the technology is deployed by leading healthcare organizations, including Clalit Health Services, Israel’s largest Health Maintenance Organization (HMO), as well as additional clinical partners worldwide.

To date, more than 250,000 home ultrasound scans have been performed using the Pulsenmore platform, creating the world’s largest real-world datasets of prenatal home ultrasound scans. This unique dataset provides a strong foundation for the development and clinical validation of AI applications.

Today, every examination performed through the platform is reviewed in its entirety by a physician before results are returned to the patient. The AI applications developed through the project are designed to streamline this workflow by automatically identifying key ultrasound parameters and presenting the findings to the physician. This is expected to enable clinicians to focus on the most clinically relevant information, reduce review time, deliver results to patients more quickly and expand the number of patients they can support, helping address the growing global shortage of skilled healthcare professionals.

As part of the program, Pulsenmore will collaborate with Beilinson Hospital, part of the Clalit Health Services network, on the development and clinical validation of the Company’s AI applications.

Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, commented: “This program is about much more than artificial intelligence. It represents the next stage in the evolution of our platform. Our goal is to equip physicians with tools that enable them to work more efficiently, focus on what matters most and care for more patients without compromising quality. The combination of our unique dataset, collaborations with leading healthcare organizations and the government-backed regulatory framework provided by this program lays the foundation for an intelligent AI-powered software layer that is expected to continue to expand the capabilities of our platform, creating increasing value for healthcare providers, health systems and patients.”

About Pulsenmore

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com

This press release contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “goal,” “due,” “predict,” “plan,” “project,” “continue,” “potential,” “positioned,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected outcome of the Sandbox Program. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Annual Report on Form 20-F, filed with the SEC on March 30, 2026. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

Investor Contact:

Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com

Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States 

FDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States 

Ramat Gan, Israel, June 24, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a strategic partnership with Ouma Health, a leading provider of virtual maternity care solutions in the United States. 

Through the collaboration, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy. 

For Pulsenmore, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide. 

“Maternal healthcare is undergoing a fundamental transformation toward more connected, patient-centered care models,” said Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore. “By partnering with Ouma Health, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.” 

“At Ouma, we care for patients who often face significant geographic and logistical barriers to prenatal care, including those living in maternity deserts and underserved communities,” said Dr. Sina Haeri, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete, especially for patients who cannot easily access specialty care in person. 

Maternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access, patient engagement, and care coordination, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models. 

The collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems, maternity care providers, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care, helping healthcare providers expand access, improve patient engagement, and deliver more connected pregnancy care beyond traditional clinical settings. 

About Pulsenmore 

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com 

 

About Ouma Health 

Ouma Health is the nation’s largest independent maternity telemedicine company, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists, Ouma is committed to equity, innovation, and outcomes, serving patients in all 50 states through partnerships with major payors, health systems, OB groups, FQHCs, reproductive agencies, and employers. For more information, visit www.oumahealth.com. 

 

This press release contains forward-looking statements. In particular, statements using words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “contemplate,” “do not believe,” “aim,” “goal,” “due,” “predict,” “plan,” “project,” “continue,” “potential,” “positioned,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law. 

 

Investor Contact: 

 

Miri Segal-Scharia 

MS-IR LLC 

msegal@ms-ir.com